Industry:	MedTech/Life Sciences Riverdale, MD www.medcurainc.com
Contact:	Larry Tiffany, CEO (301) 529-4943. ltiffany@medcurainc.com
Financing:	$10.5M in equity and $5.5M in grants
Summary:	Medcura's advanced wound treatment platform provides rapid and reliable bleeding management while creating an antibacterial healing environment. This technology has been developed into a versatile hemostatic product line targeting military/trauma, surgical and even consumer applications. Medcura combines the use of safe, inert ingredients with proprietary chemistry that can be delivered in easy-to-use formats that require no preparation or special handling, with the Company's "Breakthrough" product Life Foam™ leading the expansion into internal military and surgical applications.
Company Stage:	Commercialized products being sold at CVS and on Amazon supported by multiple FDA clearances (hemostatic and antibacterial bandages and gels) while high-value surgical/military products have successfully been evaluated in established pre-clinical models. Clinical trials are planned for 2022.
Team:	Seasoned Sr. Execs, supported by growing young technical core (see https://medcurainc.com/team.html for bios)
Accountants:	Snyder Cohn supported by Rich Vincent (Medcura CFO)
Counsel:	Morgan, Lewis & Bockius LLP

Summary of Medcura's Business

Medcura is the next great advanced materials Company to enter the medical device industry. The Company has developed a line of FDA cleared hemostatic products for clinical and consumer applications, the first of which is now available on Amazon and at >6,000 CVS stores in the US with other retail pharmacies and mass distributors to follow in early 2022. Sales have already justified the removal of the market leading product from the shelves.

Medcura combines the use of safe, inert ingredients with proprietary chemistry to design products that treat all types of bleeding even when caused by military conflict or traumatic accidents. To provide perspective on Medcura's patented high-performance platform, the US FDA recently designated its first internal product as a "Breakthrough device". This important new product was designed through a grant-supported collaboration with the US Military resulting in an injectable foam that can decisively

treat internal non-compressible severe hemorrhage, currently the largest source of in-combat mortality faced by the US Military. Through this funding, Meducra was required to manufacture and evaluate a broad sampling of formulations, including certain gels that have now shown efficacy and safety in well-established models used for surgical applications. The Company is currently pursuing a lead surgical candidate that it believes has the opportunity to disrupt the >$3B worldwide surgical hemostat market.

Business Model: The Company relies on a lean approach to building and scaling our business. By leveraging our versatile and proprietary technology platform to meet clear unmet market needs, the Company has a proven track-record of cost-effectively developing disruptive high-performance hemostats, achieving their regulatory clearance and then demonstrating their clinical and economic advantages to clinicians, hospitals and patients. Medcura has targeted markets where our disruptive products provide benefit to potential sales and marketing partners that spend very little on R&D and require the eventual acquisition of new products and technologies to support revenue growth.

Differentiation across targeted high-value markets

Although there are many approaches currently being employed to manage bleeding, none possess the advanced performance, ease of application, and pricing power of Medcura's product offerings.

Product/Market	Standard of Care	Medcura's competitive advantages
Rapid-Seal® First Aid & OTC Wound treatment (gels & adhesive bandages)	Advanced 1st Aide: WoundSeal, Blood Stop, Liquid Bandages More typical 1st aid: Band-aid	• Higher-performance hemostat that is also antibacterial • Ease of use • More durable and flexible seals • Greater ability to manage persistent bleeding • Independent of clotting cascade
R³ ™ Vascular Closure	Compressive wristbands (e.g., Terumo TR Band, Merritt Prelude/Sync Bands), Medtronic TraClet band, D-Stat)	• More rapid time to hemostasis • Reduced compressive force • Improved vascular seal and more durable integral clot (reducing re-bleeding and bruising)
LifeFoam™/Trauma/Military	Military (non-compressible bleeding): ResQFoam, X-Stat	• Does not create compressive damage to patient • Highly expandable foam allows for more "blind" delivery
LifeGel™/Surgical	Floseal, Surgicel, Gelfoam (all + Thrombin)	• Does not require thrombin • No preparation, just open and use • No cold chain storage • Improved value (e.g., larger unit @ discount to market) • Higher margins • Pricing power and flexibility

Regulatory Path:

FDA Cleared Products

Rapid-Seal:

K172010 *Rx*: Indicated for Management for the management of moderately to heavily exuding chronic wounds and acute wounds. Under medical supervision, may be used for management of pressure sores, diabetic ulcers, leg ulcers, donor sites and graft sites, surgical wounds, skin abrasions and lacerations, 1st and 2nd degree burns, and trauma wounds.

K180152 *OTC*: Indicated for local management of bleeding such as laceration and minor bleeding.

K182811 *OTC*: Indicted for use as an antibacterial material and barrier, preventing growth of bacteria.

K192667 *OTC*: Indicated for use under non-sterile processing

For sale in CVS and on Amazon

R^3:

K143466 *Rx*: Indicated for use, under the direction of a healthcare professional, in the management of bleeding wounds such as vascular access sites and percutaneous catheters or tubes.
Clinically evaluated but not commercialized.

Pending FDA Review

LifeFoam:

Designated as a "Breakthrough" Device by the US FDA, Class III pathway for acute implantable use (n=<50 for clinical trial)

LifeGel:

Pre-sbumission being reviewed by the USFDA, expected to follow typical Class III pathway for surgical hemostats following well established pre-clinical and clinical evaluation; Submission for Breakthrough Designation planned for Q4 '21

Intellectual Property:

- ✓ 7 Issued US Patents & 1 granted EU patent; numerous applications with advanced innovation in prosecution or being submitted
- ✓ Numerous trademarks
- ✓ Deep in-process formulation and manufacturing know how
  {In depth IP matrix available in our Data Room under CDA}

Traction

- ✓ Increasing weekly sales since launch, expanding online and across other brick and mortar retailers while engaging parallel vertical markets (e.g., military, industrial, eldercare, sports medicine) to distribute same SKUs
- ✓ Publication of clinical results from the University of Chicago (UCM) demonstrating superior clinical performance to the current standard of care
  https://www.medcurainc.com/publications/16998937.pdf
- ✓ >$5M in non-dilutive grants from NSF & US Military
- ✓ Multiple FDA clearances based on clear results demonstrating hemostatic and antibacterial marketing claims

Product Performance

- ✓ Multiple successful submissions, review and clearance for Biocompatibility of bandages, gels and patches by the US FDA
- ✓ Clearance of antibacterial label claim upon submission of evidence against MRSA, Staph and other formidable bacteria
- ✓ Multiple implantation studies in well-established large and small animal models stopping bleed rates from 1-4, with no reported adverse events or unacceptable evidence of immunogenicity
- ✓ No adverse events reported in recent study from UCM (e.g., no radial artery occlusion, pseudoaneurysms, cutaneous inflammation or discomfort, re-bleeding or significant bruising